Verona Pharma plc (VRNA) Announces Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COP

Go back to Verona Pharma plc (VRNA) Announces Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COP

Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD

February 2, 2021 2:00 AM EST

Primary and secondary lung function endpoints met

Results support twice-daily dosing

LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces... More